Klinische Studie

PROCARE – PROstate Cancer Real World Evidence Registry(PROCARE)This prospective real-world data and long-term follow-up registry aims at documenting routine treatment of patients with metastatic PCA and patients with biochemical recurrence after local treatment.
Krankheitsentität(en) Prostata
StudientypBeobachtungsstudie
Wesentliche Einschlusskriterien• Adult prostate cancer patients (age ≥18 years). • Diagnosis at time of study inclusion o Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof) o Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or o Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or o Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line) • Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, … line). • For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient. • Patients, who are able and willing to sign the informed consent form
Wesentliche AusschlusskriterienPatients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician
Statusrekrutierend
Ansprechpartner & KontaktCaritas-Krankenhaus St. Josef RegensburgUrologieStudienzentrale0941 7823506uro-studienzentrum(at)csj.de
zurück